Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2005 1
2006 1
2007 6
2009 4
2010 7
2011 9
2012 7
2013 7
2014 3
2015 4
2016 6
2017 6
2018 15
2019 9
2020 12
2021 7
2022 11
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, van Nimwegen M, Lau SP, Latupeirissa K, Schetters S, van Kooyk Y, Boon L, Moyaart A, Mueller YM, Katsikis PD, Eggermont AM, Vroman H, Stadhouders R, Hendriks RW, Thüsen JV, Grünhagen DJ, Verhoef C, van Hall T, Aerts JG. Dammeijer F, et al. Among authors: van hall t. Cancer Cell. 2020 Nov 9;38(5):685-700.e8. doi: 10.1016/j.ccell.2020.09.001. Epub 2020 Oct 1. Cancer Cell. 2020. PMID: 33007259 Free article.
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.
Fransen MF, Schoonderwoerd M, Knopf P, Camps MG, Hawinkels LJ, Kneilling M, van Hall T, Ossendorp F. Fransen MF, et al. Among authors: van hall t. JCI Insight. 2018 Dec 6;3(23):e124507. doi: 10.1172/jci.insight.124507. JCI Insight. 2018. PMID: 30518694 Free PMC article.
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance.
van Gulijk M, van Krimpen A, Schetters S, Eterman M, van Elsas M, Mankor J, Klaase L, de Bruijn M, van Nimwegen M, van Tienhoven T, van Ijcken W, Boon L, van der Schoot J, Verdoes M, Scheeren F, van der Burg SH, Lambrecht BN, Stadhouders R, Dammeijer F, Aerts J, van Hall T. van Gulijk M, et al. Among authors: van hall t. Sci Immunol. 2023 May 19;8(83):eabn6173. doi: 10.1126/sciimmunol.abn6173. Epub 2023 May 19. Sci Immunol. 2023. PMID: 37205768
Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
Kumar S, Schoonderwoerd MJA, Kroonen JS, de Graaf IJ, Sluijter M, Ruano D, González-Prieto R, Verlaan-de Vries M, Rip J, Arens R, de Miranda NFCC, Hawinkels LJAC, van Hall T, Vertegaal ACO. Kumar S, et al. Among authors: van hall t. Gut. 2022 Nov;71(11):2266-2283. doi: 10.1136/gutjnl-2021-324834. Epub 2022 Jan 24. Gut. 2022. PMID: 35074907 Free PMC article.
Therapeutic cancer vaccines.
Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Melief CJ, et al. Among authors: van hall t. J Clin Invest. 2015 Sep;125(9):3401-12. doi: 10.1172/JCI80009. Epub 2015 Jul 27. J Clin Invest. 2015. PMID: 26214521 Free PMC article. Review.
Monalizumab: inhibiting the novel immune checkpoint NKG2A.
van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E. van Hall T, et al. J Immunother Cancer. 2019 Oct 17;7(1):263. doi: 10.1186/s40425-019-0761-3. J Immunother Cancer. 2019. PMID: 31623687 Free PMC article. Review.
Future Challenges in Cancer Resistance to Immunotherapy.
van Elsas MJ, van Hall T, van der Burg SH. van Elsas MJ, et al. Among authors: van hall t. Cancers (Basel). 2020 Apr 10;12(4):935. doi: 10.3390/cancers12040935. Cancers (Basel). 2020. PMID: 32290124 Free PMC article. Review.
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses.
Groeneveldt C, van Hall T, van der Burg SH, Ten Dijke P, van Montfoort N. Groeneveldt C, et al. Among authors: van hall t. Trends Immunol. 2020 May;41(5):406-420. doi: 10.1016/j.it.2020.03.003. Epub 2020 Mar 27. Trends Immunol. 2020. PMID: 32223932 Review.
Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S.
Harryvan TJ, Visser M, de Bruin L, Plug L, Griffioen L, Mulder A, van Veelen PA, van der Heden van Noort GJ, Jongsma ML, Meeuwsen MH, Wiertz EJ, Santegoets SJ, Hardwick JC, Van Hall T, Neefjes J, Van der Burg SH, Hawinkels LJ, Verdegaal EM. Harryvan TJ, et al. Among authors: van hall t. J Immunother Cancer. 2022 Mar;10(3):e003591. doi: 10.1136/jitc-2021-003591. J Immunother Cancer. 2022. PMID: 35264435 Free PMC article.
113 results